Positive results have been reported following the completion of the CTP-543 Phase 2 trial. More than 75% of patients receiving two daily 12mg dosages of CTP-543 confirmed that their alopecia had “very much improved” or “much improved” after 24 weeks.
Plans for phase 3 are on the way and scheduled to start in 2020.
To see the full article, click here.
You can also listen to the webcast from Sept 3rd 2019 detailing the results of phase 2.
